{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:06:37Z","timestamp":1791471997292,"version":"4.3.4"},"reference-count":13,"publisher":"BMJ","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.n1682","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:55:47Z","timestamp":1625489747000},"page":"n1682","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":159,"title":["Aducanumab for Alzheimer\u2019s disease?"],"prefix":"10.1136","author":[{"given":"Sebastian","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Merrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Brayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"2021070607500710000_374.jul05_4.n1682.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1503"},{"key":"2021070607500710000_374.jul05_4.n1682.2","doi-asserted-by":"crossref","unstructured":"Walsh S, King E, Brayne C. France removes state funding for dementia drugs. 2019.","DOI":"10.1136\/bmj.l6930"},{"key":"2021070607500710000_374.jul05_4.n1682.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"2021070607500710000_374.jul05_4.n1682.4","unstructured":"US Food & Drug Administration. Combined FDA and applicant PCNS drugs advisory committee briefing document. 2020. https:\/\/www.fda.gov\/media\/143502\/download"},{"key":"2021070607500710000_374.jul05_4.n1682.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n156"},{"key":"2021070607500710000_374.jul05_4.n1682.6","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12379"},{"key":"2021070607500710000_374.jul05_4.n1682.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"},{"key":"2021070607500710000_374.jul05_4.n1682.8","unstructured":"US Food and Drug Administration. FDA\u2019s decision to approve new treatment for Alzheimer\u2019s disease. 2021. www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease"},{"key":"2021070607500710000_374.jul05_4.n1682.9","unstructured":"US Food and Drug Administration. Prescribing information: aducanumab. 2021. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf."},{"key":"2021070607500710000_374.jul05_4.n1682.10","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf"},{"key":"2021070607500710000_374.jul05_4.n1682.11","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-01546-2"},{"key":"2021070607500710000_374.jul05_4.n1682.12","unstructured":"Reuters. Lilly to seek accelerated FDA approval for Alzheimer\u2019s drug this year. Reuters 2021. www.reuters.com\/business\/healthcare-pharmaceuticals\/lilly-seek-fda-approval-alzheimers-drug-this-year-2021-06-24\/"},{"key":"2021070607500710000_374.jul05_4.n1682.13","unstructured":"World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. 2019. https:\/\/www.who.int\/publications\/i\/item\/risk-reduction-of-cognitive-decline-and-dementia"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.n1682","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.n1682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T14:50:29Z","timestamp":1625583029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.n1682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":13,"alternative-id":["10.1136\/bmj.n1682"],"URL":"https:\/\/doi.org\/10.1136\/bmj.n1682","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}